Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Intrinsic Value
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. [ Read More ]
The intrinsic value of one
BCLI
stock under the Base Case scenario is
0.019
USD.
Compared to the current market price of 0.5408 USD,
Brainstorm Cell Therapeutics Inc
is
Overvalued by 96%.
Brainstorm Cell Therapeutics Inc's market capitalization is 37m USD.
BCLI stock price is 0.5408 USD.
BCLI stock (0.019 USD) is 96% less than its price (0.5408 USD).
BCLI. Open Relative Valuation
BCLI has upside potential of 372% compared to the average analyst price target.
Open Wall St Estimates
BCLI has negative Free Cash Flow for the last twelve months.
BCLI has positive three-year average ROE (Return on Equity): 11%. The company is efficient at transforming stockholders' equity into net income.
BCLI has negative Operating Income for the last twelve months.
BCLI has negative Net Income for the last twelve months.
BCLI's ROE (Return on Equity) has significantly increased in the last 3 years from -134% to 436%.
BCLI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 215% to 1 534%.
BCLI's ROE (Return on Equity) for the past 12 months is very high and is equal to 436%.
BCLI's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 1 534%.
BCLI's long-term liabilties (9m USD) exceed its long-term assets (4m USD).
BCLI's short-term liabilties (8m USD) exceed its short-term assets (2m USD).
BCLI has very high three-year average ROIC (Return on Invested Capital): 198%. The company is very efficient at using invested capital to generate operating income.
BCLI's D/E (Debt to Equity) is very low and is equal to 0.
BCLI's Altman Z-Score is very low and is equal to -89.17.
Valuation Backtest
Brainstorm Cell Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
BCLI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Brainstorm Cell Therapeutics Inc
Balance Sheet Decomposition
Brainstorm Cell Therapeutics Inc
| Current Assets | 1.9m |
| Cash & Short-Term Investments | 1.3m |
| Receivables | 51k |
| Other Current Assets | 548k |
| Non-Current Assets | 2.3m |
| PP&E | 2.1m |
| Other Non-Current Assets | 207k |
| Current Liabilities | 7.8m |
| Accounts Payable | 5m |
| Accrued Liabilities | 1.8m |
| Other Current Liabilities | 1m |
| Non-Current Liabilities | 1.3m |
| Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Brainstorm Cell Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-21.4m
USD
|
|
Operating Income
|
-21.4m
USD
|
|
Other Expenses
|
4.2m
USD
|
|
Net Income
|
-17.2m
USD
|
Free Cash Flow Analysis
Brainstorm Cell Therapeutics Inc
What is Free Cash Flow?
BCLI Profitability Score
Profitability Due Diligence
Brainstorm Cell Therapeutics Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Brainstorm Cell Therapeutics Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
BCLI Solvency Score
Solvency Due Diligence
Brainstorm Cell Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Brainstorm Cell Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCLI Price Targets Summary
Brainstorm Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
BCLI
is 2.55 USD
with a low forecast of 2.525 USD and a high forecast of 2.625 USD.
Ownership
BCLI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BCLI Price
Brainstorm Cell Therapeutics Inc
| Average Annual Return | -12.24% |
| Standard Deviation of Annual Returns | 32.95% |
| Max Drawdown | -99% |
| Market Capitalization | 37m USD |
| Shares Outstanding | 68 341 904 |
| Percentage of Shares Shorted | 2.05% |
Company Profile
Brainstorm Cell Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
Contact
IPO
Employees
Officers
The intrinsic value of one
BCLI
stock under the Base Case scenario is
0.019
USD.
Compared to the current market price of 0.5408 USD,
Brainstorm Cell Therapeutics Inc
is
Overvalued by 96%.
You don't have any saved screeners yet
